Generic drug development overview MCQs With Answer

Generic Drug Development Overview MCQs With Answer

Generic drug development sits at the intersection of science, regulation, and quality systems. For M. Pharm students specializing in Regulatory Affairs (MPH 104T), mastering concepts like ANDA pathways, bioequivalence, BCS-based biowaivers, stability, GMP, and post-approval change management is essential. This quiz compiles exam-focused, practice-ready MCQs covering key global frameworks (FDA, EMA, WHO, ICH) and India-relevant considerations. You will test your understanding of the Orange Book, patent certifications, therapeutic equivalence codes, ICH Q8–Q10 and M9, dissolution similarity, DMFs, SUPAC, and topical generic methodologies. Each question is designed to go beyond definitions, pressing you to apply principles the way regulators and industry do in real submissions and inspections.

Q1. The primary regulatory pathway for a U.S. generic tablet with identical strength, dosage form, route, and labeling (with permissible differences) to an RLD is:

• New Drug Application (NDA) under section 505(b)(1)
• Abbreviated New Drug Application (ANDA) under section 505(j)
• Hybrid application under section 505(b)(2)
• Investigational New Drug (IND) application

Correct Answer: Abbreviated New Drug Application (ANDA) under section 505(j)

Q2. In a standard fasting bioequivalence study for an immediate-release product, acceptance is typically based on the 90% confidence intervals for which parameters and range?

• Cmax and Tmax within 75–133% on arithmetic scale
• AUC0–t and Cmax within 80.00–125.00% on log-transformed scale
• AUC0–inf only within 90–110% on log-transformed scale
• Ae (urinary excretion) within 80–125% on arithmetic scale

Correct Answer: AUC0–t and Cmax within 80.00–125.00% on log-transformed scale

Q3. Which statement best reflects current principles for BCS-based biowaivers for immediate-release solid oral dosage forms?

• Permitted only for BCS Class II drugs with low solubility
• Allowed for Class I (and under some agencies, Class III) if high solubility, rapid dissolution, and formulation sameness conditions are met
• Applicable to all classes if f2 ≥ 50
• Allowed only when an IVIVC Level A exists

Correct Answer: Allowed for Class I (and under some agencies, Class III) if high solubility, rapid dissolution, and formulation sameness conditions are met

Q4. The FDA Orange Book primarily provides:

• Clinical trial protocols and investigator brochures
• Therapeutic equivalence evaluations, RLD designations, and patent/exclusivity listings
• Facility GMP inspection outcomes and warning letters
• Pharmacovigilance signal detection reports

Correct Answer: Therapeutic equivalence evaluations, RLD designations, and patent/exclusivity listings

Q5. A Paragraph IV certification in an ANDA asserts that:

• The listed patent has expired
• The applicant has a license from the patent owner
• No patent information is listed for the RLD
• The listed patent is invalid, unenforceable, or will not be infringed by the generic

Correct Answer: The listed patent is invalid, unenforceable, or will not be infringed by the generic

Q6. In the Orange Book, an “AB” therapeutic equivalence code indicates:

• No bioequivalence data were submitted
• Bioequivalence has been demonstrated and products are substitutable
• Products are not substitutable due to clinical concerns
• The product is discontinued

Correct Answer: Bioequivalence has been demonstrated and products are substitutable

Q7. For solutions for injection intended for the same route and concentration as the RLD, in vivo bioequivalence may be waived when:

• Active ingredient is different but same class
• Inactive ingredients qualitatively and quantitatively match critical excipients and product is Q1/Q2 the same
• Only the container-closure is identical
• Osmolality differs by more than 20%

Correct Answer: Inactive ingredients qualitatively and quantitatively match critical excipients and product is Q1/Q2 the same

Q8. For two dissolution profiles to be considered similar using the f2 similarity factor, the generally accepted threshold is:

• f2 ≥ 25
• f2 ≥ 40
• f2 ≥ 50
• f2 ≥ 75

Correct Answer: f2 ≥ 50

Q9. ICH Q8, Q9, and Q10 collectively address:

• Clinical safety, efficacy, and pharmacovigilance
• Quality by Design, Quality Risk Management, and Pharmaceutical Quality System
• Bioequivalence, biowaivers, and biostatistics
• Stability testing, impurities, and residual solvents

Correct Answer: Quality by Design, Quality Risk Management, and Pharmaceutical Quality System

Q10. The recommended long-term stability storage condition for products intended for Climatic Zone IVb (many hot/humid regions) per ICH/WHO is typically:

• 25°C/60% RH
• 30°C/65% RH
• 30°C/75% RH
• 40°C/75% RH

Correct Answer: 30°C/75% RH

Q11. The typical stages of process validation as per modern lifecycle approach are:

• Design Qualification, Installation Qualification, Operational Qualification
• Process Design, Process Performance Qualification, Continued Process Verification
• Method Development, Method Qualification, Method Validation
• User Requirement Specification, Risk Analysis, Factory Acceptance Test

Correct Answer: Process Design, Process Performance Qualification, Continued Process Verification

Q12. A standard two-treatment, two-period, two-sequence crossover (2×2×2) BE study primarily helps control for:

• Inter-occasion variability only
• Sequence, period, and subject effects
• Carryover effects entirely
• Food effect without a fed arm

Correct Answer: Sequence, period, and subject effects

Q13. In U.S. DMF classification, the appropriate DMF type for a drug substance (API) is:

• Type I
• Type II
• Type III
• Type IV

Correct Answer: Type II

Q14. Which ICH guideline specifically addresses BCS-based biowaivers and harmonizes criteria across regions?

• ICH Q6A
• ICH Q1A(R2)
• ICH M9
• ICH E6(R2)

Correct Answer: ICH M9

Q15. Highly variable drugs (HVDs), typically with within-subject CV ≥ 30%, are often evaluated using:

• Parallel designs with widened 70–143% limits
• Replicate crossover designs with reference-scaled average bioequivalence
• Single-dose, single-period designs
• Food-effect studies only

Correct Answer: Replicate crossover designs with reference-scaled average bioequivalence

Q16. A 505(b)(2) application is best described as:

• An ANDA relying solely on equivalence to an RLD
• A full NDA with only new clinical data
• A hybrid pathway that bridges to literature or prior findings while proposing changes (e.g., new dosage form)
• An IND for early-phase trials

Correct Answer: A hybrid pathway that bridges to literature or prior findings while proposing changes (e.g., new dosage form)

Q17. For immediate-release tablets seeking a Class III BCS-based biowaiver under FDA expectations, formulation criteria typically include:

• Q1/Q2 sameness to RLD and very rapid dissolution (≥85% in 15 minutes)
• Any excipient changes are acceptable if f2 ≥ 50
• Q3 microstructure sameness only
• No restrictions on disintegrant levels

Correct Answer: Q1/Q2 sameness to RLD and very rapid dissolution (≥85% in 15 minutes)

Q18. For semi-solid topical generics (e.g., creams), current tools to establish bioequivalence include:

• Only serum PK endpoints
• In vitro release testing (IVRT), in vitro permeation testing (IVPT), and Q3 microstructure characterization per product-specific guidances
• Organoleptic evaluation alone
• Urinary excretion studies

Correct Answer: In vitro release testing (IVRT), in vitro permeation testing (IVPT), and Q3 microstructure characterization per product-specific guidances

Q19. In the eCTD structure of an ANDA, the module that contains the majority of quality/CMC information is:

• Module 1
• Module 2
• Module 3
• Module 4

Correct Answer: Module 3

Q20. Under FDA’s post-approval change regulations (21 CFR 314.70) and SUPAC guidance, a major change (e.g., certain significant formulation or site changes) generally requires:

• Annual report with distribution before approval
• Changes Being Effected in 0 days (CBE-0)
• Changes Being Effected in 30 days (CBE-30)
• Prior Approval Supplement (PAS) before distribution

Correct Answer: Prior Approval Supplement (PAS) before distribution

Download